Van Wyk Lizelle, Gupta Samir, Lawrenson John, de Boode Willem-Pieter
Division Neonatology, Department of Pediatrics and Child Health, Stellenbosch University and Tygerberg Children's Hospital, Cape Town, South Africa.
Department of Engineering and Medical Physics, Durham University, Durham, United Kingdom.
Front Pediatr. 2022 Mar 17;10:851850. doi: 10.3389/fped.2022.851850. eCollection 2022.
Electrical biosensing technology (EBT) is an umbrella term for non-invasive technology utilizing the body's fluctuating resistance to electrical current flow to estimate cardiac output. Monitoring cardiac output in neonates may allow for timely recognition of hemodynamic compromise and allow for prompt therapy, thereby mitigating adverse outcomes. For a new technology to be safely used in the clinical environment for therapeutic decisions, it must be proven to be accurate, precise and be able to track temporal changes. The aim of this systematic review was to identify and analyze studies that describe the accuracy, precision, and trending ability of EBT to non-invasively monitor Left ventricular cardiac output and/or stroke volume in neonates.
A qualitative systematic review was performed. Studies were identified from PubMed NCBI, SCOPUS, and EBSCOHost up to November 2021, where EBT technologies were analyzed in neonates, in comparison to a reference technology. Outcome measures were bias, limits of agreement, percentage error for agreement studies and data from 4-quadrant and polar plots for trending studies. Effect direction plots were used to present results.
Fifteen neonatal studies were identified, 14 for agreement and 1 for trending analysis. Only thoracic electrical biosensing technology (TEBT), with transthoracic echocardiography (TTE) as the comparator, studies were available for analyzes. High heterogeneity existed between studies. An equal number of studies showed over- and underestimation of left ventricular output parameters. All studies showed small bias, wide limits of agreement, with most studies having a percentage error >30%. Sub-analyses for respiratory support mode, cardiac anomalies and type of technology showed similar results. The single trending study showed poor concordance, high angular bias, and poor angular concordance.
Overall, TEBT shows reasonable accuracy, poor precision, and non-interchangeability with TTE. However, high heterogeneity hampered proper analysis. TEBT should be used with caution in the neonatal population for monitoring and determining therapeutic interventions. The use of TEBT trend monitoring has not been sufficiently studied and requires further evaluation in future trials.
电生物传感技术(EBT)是一个统称,指利用人体对电流流动的波动电阻来估计心输出量的非侵入性技术。监测新生儿的心输出量可能有助于及时识别血流动力学损害并及时进行治疗,从而减轻不良后果。要使一项新技术能够安全地用于临床环境以做出治疗决策,必须证明其准确、精确且能够跟踪时间变化。本系统评价的目的是识别和分析描述EBT非侵入性监测新生儿左心室心输出量和/或每搏输出量的准确性、精确性和趋势跟踪能力的研究。
进行了一项定性系统评价。截至2021年11月,从PubMed NCBI、SCOPUS和EBSCOHost中检索研究,其中对EBT技术在新生儿中的应用与参考技术进行了比较分析。结果指标包括偏倚、一致性界限、一致性研究的百分比误差以及趋势研究的四象限和极坐标图数据。采用效应方向图展示结果。
共识别出15项新生儿研究,其中14项用于一致性分析,1项用于趋势分析。仅有用经胸超声心动图(TTE)作为对照的胸段电生物传感技术(TEBT)的研究可供分析。各研究之间存在高度异质性。数量相等的研究显示左心室输出参数存在高估和低估情况。所有研究均显示偏倚较小、一致性界限较宽,大多数研究的百分比误差>30%。对呼吸支持模式、心脏异常和技术类型的亚组分析显示了类似结果。唯一的趋势研究显示一致性差、角度偏倚高且角度一致性差。
总体而言,TEBT显示出合理的准确性、较差的精确性,且与TTE不可互换。然而,高度异质性阻碍了恰当的分析。在新生儿群体中使用TEBT进行监测和确定治疗干预时应谨慎。TEBT趋势监测的应用尚未得到充分研究,需要在未来试验中进一步评估。